Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells $11,633,048.40 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Eliyahu Sharon Kalif sold 345,810 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the transaction, the executive vice president owned 57,478 shares in the company, valued at approximately $1,933,559.92. This trade represents a 85.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Teva Pharmaceutical Industries Trading Down 0.3%

Shares of TEVA stock traded down $0.09 during trading hours on Monday, hitting $33.77. 6,005,803 shares of the company were exchanged, compared to its average volume of 9,690,522. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The company has a 50 day simple moving average of $32.94 and a two-hundred day simple moving average of $25.80. The firm has a market cap of $38.83 billion, a P/E ratio of 28.14, a P/E/G ratio of 11.33 and a beta of 0.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business’s revenue was up 11.4% on a year-over-year basis. During the same period last year, the company earned $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TEVA. Bank of America boosted their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. The Goldman Sachs Group raised their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Scotiabank increased their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. Jefferies Financial Group boosted their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average target price of $37.56.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds have recently bought and sold shares of TEVA. Norges Bank purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $1,098,060,000. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Teva Pharmaceutical Industries by 51.4% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock valued at $559,622,000 after purchasing an additional 11,334,780 shares in the last quarter. Menora Mivtachim Holdings LTD. raised its position in Teva Pharmaceutical Industries by 31.9% in the second quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock worth $645,148,000 after acquiring an additional 9,303,978 shares in the last quarter. Soundwatch Capital LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $143,533,000. Finally, Wellington Management Group LLP grew its holdings in shares of Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after acquiring an additional 6,878,304 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.